{"id":"b55r1-and-placebo-for-b55r2","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=B55R1 and placebo for B55R2","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:19:28.424836+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:19:33.791723+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=B55R1 and placebo for B55R2","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:19:34.157168+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL521875/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:19:35.350902+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of B55R1 is not well understood, but it is thought to involve the inhibition of a key enzyme involved in the regulation of various cellular processes. This inhibition leads to a decrease in the production of a specific molecule, which in turn leads to the therapeutic effects of the drug.","oneSentence":"B55R1 is a small molecule drug that works by inhibiting the activity of a specific enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:16.364Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:19:37.065853+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT07230184","phase":"PHASE4","title":"To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR","status":"COMPLETED","sponsor":"AJU Pharm Co., Ltd.","startDate":"2022-04-28","conditions":"Non-Proliferative Diabetic Retinopathy","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL521875"},"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"B55R1 and placebo for B55R2","genericName":"B55R1 and placebo for B55R2","companyName":"AJU Pharm Co., Ltd.","companyId":"aju-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"B55R1 is a small molecule drug that works by inhibiting the activity of a specific enzyme. Used for Atrial fibrillation for stroke prevention, Hypertension.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:19:37.065853+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}